ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

BIIB Biogen Inc

221.42
3.91 (1.80%)
07 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Biogen Inc NASDAQ:BIIB NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  3.91 1.80% 221.42 221.42 221.95 222.40 218.29 218.64 1,199,849 01:00:00

Biogen to Report First Quarter 2017 Financial Results on April 25, 2017

27/03/2017 9:01pm

Business Wire


Biogen (NASDAQ:BIIB)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Biogen Charts.

Biogen Inc. (NASDAQ:BIIB) today announced it will report first quarter 2017 financial results on Tuesday, April 25, 2017, before the financial markets open.

Following the release of the financials, the Company will host a live webcast where Biogen management will discuss the financial results, at 8:30 am ET. To access the live webcast, please go to the investor relations section of Biogen’s website at www.biogen.com/investors. Following the live webcast, an archived version of the call will be available at the same URL.

About Biogen

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS). Building on its heritage in biologics, Biogen also manufactures and commercializes high-quality biosimilars. For more information, please visit www.biogen.com. Follow us on social media – Twitter, LinkedIn, Facebook, YouTube.

BiogenKaren Jewell, 781-464-2442Investor Relations

1 Year Biogen Chart

1 Year Biogen Chart

1 Month Biogen Chart

1 Month Biogen Chart

Your Recent History

Delayed Upgrade Clock